Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Biostar Pharma Says Gelatin Scandal Will Cut Q2 Revenues in Half

publication date: Aug 8, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Biostar Pharma of Xianyang warned investors that its second quarter was severely hurt by China’s gelatin scandal, which began in April of this year. Because Biostar was ordered to stop all sales of gelatin products, the company’s Q2 revenues will be cut in half from the nearly $16 million it recorded in Q1. Stressing the positive, Biostar reported the Xianyang SFDA gave permission on July 30 to re-start its production of gelatin-based capsules. The company expects Q3 to be much improved, while it hopes Q4 will see revenues return to normal levels. More details....

Stock Symbol: (NSDQ: BSPM)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors